Annexon Biosciences (ANNX) Stock Statistics & Valuation Metrics

Annexon Biosciences has a market cap or net worth of $746.94M. The enterprise value is $963.14M.

Market Cap

$746.94M

Enterprise Value

$963.14M

Annexon Biosciences has 189,579,130 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

189,579,130

Owned by Insiders

6.16%

Owned by Institutions

40.23%

Annexon Biosciences’s return on equity (ROE) is -0.98 and return on invested capital (ROIC) is -90.99%.

Return on Equity (ROE)

-0.98

Return on Assets (ROA)

-0.74

Return on Invested Capital (ROIC)

-90.99%

Return on Capital Employed (ROCE)

-0.92

Revenue Per Employee

0

Profits Per Employee

-2.25M

Employee Count

92

Asset Turnover

0.00

Inventory Turnover

0.00

The current PE Ratio of Annexon Biosciences is -3.61. Annexon Biosciences’s PEG ratio is -0.42.

PE Ratio

-3.61

PS Ratio

0.00

PB Ratio

4.53

Price to FCF

-3.55

Price to Operating Cash Flow

-4.36

PEG Ratio

-0.42

In the last 12 months, Annexon Biosciences had revenue of 0 and earned -206.69M in profits. Earnings per share was -1.34.

Revenue

0

Gross Profit

-3.69M

Operating Income

-216.41M

Pretax Income

-206.69M

Net Income

-206.69M

EBITDA

-204.52M

Earnings Per Share (EPS)

-1.34

In the last 12 months, operating cash flow was -193.03M and capital expenditures -185,000, giving a free cash flow of -193.22M billion.

Operating Cash Flow

-193.03M

Free Cash Flow

-193.22M

Free Cash Flow per Share

-0.96

Annexon Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-27.39%

Earnings Yield

-23.42%

Beta

1.42

52-Week Price Change

32.18%

50-Day Moving Average

4.20

200-Day Moving Average

5.20

Relative Strength Index (RSI)

56.13

Average Volume (3m)

3.16M

Annexon Biosciences upcoming earnings date is Nov 16, 2026, TBA (Not Confirmed).

Last Earnings Date

Aug 12, 2026

Next Earnings Date

Nov 16, 2026

Ex-Dividend Date

―

Annexon Biosciences as a current ratio of 5.68, with Debt / Equity ratio of 12.38%

Current Ratio

5.68

Quick Ratio

5.68

Debt to Market Cap

0.00

Net Debt to EBITDA

0.66

Interest Coverage Ratio

0.00

In the past 12 months, Annexon Biosciences has paid 0 in taxes.

Income Tax

0

Effective Tax Rate

0.00

Annexon Biosciences EV to EBITDA ratio is -2.65, with an EV/FCF ratio of -2.75.

EV to Sales

0.00

EV to EBITDA

-2.65

EV to Free Cash Flow

-2.75

EV to Operating Cash Flow

-2.75

Annexon Biosciences has $209.24M in cash and marketable securities with $24.65M in debt, giving a net cash position of $184.59M billion.

Cash & Marketable Securities

$209.24M

Total Debt

$24.65M

Net Cash

$184.59M

Net Cash Per Share

$0.97

Tangible Book Value Per Share

$0.93

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin

0.00%

Operating Margin

0.00%

Pretax Margin

0.00%

Net Profit Margin

0.00%

EBITDA Margin

0.00%

EBIT Margin

0.00%

The average price target for Annexon Biosciences is $17.16, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target

$17.16

Price Target Upside

309.47% Upside

Analyst Consensus

Strong Buy

Analyst Count

7

Revenue Growth Forecast

―

EPS Growth Forecast

10.96%

Smart Score

8

AI Score

52